局限前列腺癌大分割放疗:ASTRO、ASCO与AUA循证指南执行摘要
该指南由美国放射肿瘤学会(ASTRO)牵头,联合ASCO与AUA,基于系统文献综述,针对局限前列腺癌的中等大分割(240-340 cGy/次)和超大分割(≥500 cGy/次)放疗提出推荐。指南强烈推荐中等大分割可用于各风险组选择外照射的患者,条件性推荐超大分割用于低中危患者,条件性反对高危患者常规使用超大分割。
要点
- 中等大分割放疗可推荐用于所有风险组选择外照射的患者。
- 超大分割放疗可条件性用于低中危前列腺癌,中危患者强烈鼓励参加临床试验或登记研究。
- 任何大分割方案均强烈推荐图像引导放疗,避免使用非调强三维适形技术。
核心结论
- 基于高质量证据,强烈共识推荐中等大分割放疗用于各风险组选择外照射的局限前列腺癌患者。
- 超大分割放疗条件性推荐用于低中危患者,但高危患者条件性不推荐常规使用。
研究设计与样本
- ASTRO召集工作组,基于系统文献综述,采用预定义共识构建方法和学会批准的工具对证据质量和推荐强度进行分级。
- 指南针对中等大分割(240-340 cGy/次)和超大分割(≥500 cGy/次)放疗的适应证、剂量分割及技术问题提出推荐。
主要发现
- 基于高质量证据,中等大分割在各风险组中获得强烈共识推荐。
- 超大分割在低中危患者中获条件性推荐,中危患者强烈鼓励参加临床试验或多机构登记研究。
- 高危患者常规使用超大分割外照射获条件性反对推荐。
关键数值与推荐
- 中等大分割剂量分割为每次240-340 cGy。
- 超大分割剂量分割为每次500 cGy或以上。
- 任何大分割方案均强烈推荐图像引导放疗,并避免非调强三维适形技术。
临床怎么用
- 临床医生对选择外照射的局限前列腺癌患者,可提供中等大分割放疗。
- 对低中危患者可考虑超大分割放疗,但中危患者应优先参加临床试验或登记研究。
- 实施大分割放疗时必须使用图像引导放疗,避免非调强三维适形技术。
局限性
- 当前证据基础有限,尤其是超大分割放疗,强调需要支持大规模随机临床试验。
- 指南强调临床医生与患者共同决策的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer. METHODS AND MATERIALS: The American Society for Radiation Oncology convened a task force to address 8 key questions on appropriate indications and dose-fractionation for moderately and ultrahypofractionated radiation therapy, as well as technical issues, including normal tissue dose constraints, treatment volumes, and use of image guided and intensity modulated radiation therapy. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and Society-approved tools for grading evidence quality and recommendation strength. RESULTS: Based on high-quality evidence, strong consensus was reached for offering moderate hypofractionation across risk groups to patients choosing external beam radiation therapy. The task force conditionally recommends ultrahypofractionated radiation may be offered for low- and intermediate-risk prostate cancer but strongly encourages treatment of intermediate-risk patients on a clinical trial or multi-institutional registry. For high-risk patients, the task force conditionally recommends against routine use of ultrahypofractionated external beam radiation therapy. With any hypofractionated approach, the task force strongly recommends image guided radiation therapy and avoidance of nonmodulated 3-dimensional conformal techniques. CONCLUSIONS: Hypofractionated radiation therapy provides important potential advantages in cost and convenience for patients, and these recommendations are intended to provide guidance on moderate hypofractionation and ultrahypofractionation for localized prostate cancer. The limits in the current evidentiary base-especially for ultrahypofractionation-highlight the imperative to support large-scale randomized clinical trials and underscore the importance of shared decision making between clinicians and patients.
引用
- Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. J Urol. 2019. PMID: 30759696. doi:10.1097/JU.0000000000000071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。